BioSpace News Archive

Ardelyx, Inc. announced that it has commenced an underwritten public offering of up to $80,000,000 of shares of its common stock.

Nasdaq Rule 5550(a)(2) requires the Shares to maintain a minimum bid price of US$1.00 per Share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the Shares is below US$1.00 for a period of 30 consecutive business days.

Trial of Voclosporin Meets All Primary and Secondary Endpoints with Clean Safety Profile

Published data from a second robust Phase 3 clinical trial demonstrated efficacy, safety and tolerability of ubrogepant, an orally-administered CGRP receptor antagonist

Renowned STEM Education Leader, Committed to Building Access, Joins as Museum Inaugurates a Decade of Growth

Piramal Enterprises Limited’s Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), today announced that the company will be partnering with BerGenBio ASA (OSE:BGBIO) on the development of bemcentinib for the treatment of elderly patients with relapsed Acute Myeloid Leukemia (AML).

The first UK clinical trial site for the treatment of diabetic patients with chronic limb-threatening ischemia (CLI) using a novel patient-specific regenerative therapy has opened for patient recruitment at the University Hospital of Wales in Cardiff

Highlights of the presentation, entitled “Interaction of ALS Progression and the Efficacy of MN‑166”, which will be presented by Kazuko Matsuda, M.D. Ph.D. M.P.H., Chief Medical Officer of MediciNova, Inc.

The evidence review examined all available studies on use of telemedicine for several neurologic conditions

RubrYc’s SAB will leverage synergistic expertise in structural and computational biology, translational sciences, and market and clinical insights.